Shares of Genocea Biosciences Inc. (GNCA) were up more than 94% on Thursday, following positive 12 month efficacy data from the company's phase II dose optimization trial evaluating GEN-003 for the treatment of genital herpes.
from RTT - Biotech http://ift.tt/1UXJ6jt
via IFTTT
No comments:
Post a Comment